Healthcare Partnerships Nozin already partners with The Leapfrog Group and is trusted by hundreds of hospitals and healthcare professionals, signaling strong potential for expanding into hospital systems, risk management programs, and infection prevention initiatives.

Infection Prevention Demand With a focus on nasal decolonization and MRSA/MSSA risk mitigation programs, there is a clear opportunity to upsell to care facilities seeking validated infection prevention solutions that reduce infection risk and associated costs.

Clinical Validation Clinically supported efficacy (kills 99.99% of germs) and recognition as a top infection prevention product provide credible messaging for expanding adoption in hospital procurement, outpatient centers, and long-term care facilities.

Product Suite Expansion Existing NOVA SM and NOVA℠ program offerings indicate room to cross-sell complementary hygiene and decolonization services to healthcare networks implementing MRSA/MSSA risk mitigation across departments.

SMB to Enterprise Revenue in the $10M–$25M range and a small- to mid-sized employee base suggests scalable opportunity by targeting regional health systems, IDM groups, and networked clinics that can benefit from standardized nasal antiseptic programs.